Heart Failure with Preserved Ejection Fraction (HFpEF): A Clinical Guideline Review

The management of heart failure with preserved ejection fraction (HFpEF) represents one of contemporary cardiology’s greatest challenges. For decades, therapeutic efforts centered on patients with reduced ejection fraction (HFrEF), leaving effective treatment for HFpEF—defined by a left ventricular ejection fraction (LVEF ≥ 50%) and evidence of elevated filling pressures—as an unmet clinical need.

The prevalence of HFpEF continues to rise, especially in aging populations and those with significant cardiometabolic comorbidities. Globally, HFpEF accounts for approximately half of all heart failure cases, carrying a mortality burden comparable to HFrEF.

Unlike HFrEF, which is primarily a problem of systolic pump failure, HFpEF is characterized by impaired ventricular relaxation and increased stiffness (diastolic dysfunction). This stiffness leads to high left atrial pressures, resulting in symptoms like dyspnea and exercise intolerance.

Clinicians urgently require an up-to-date, evidence-based roadmap for navigating the complex diagnostic process and implementing the optimal medical therapies that have recently emerged.

Pathophysiology and Phenotypes: Understanding Diastolic Dysfunction

Core Mechanisms of HFpEF (The ‘Cardio-Metabolic’ Model)

The pathophysiology of HFpEF is multifaceted, involving systemic inflammation that impacts the myocardium, vasculature, and skeletal muscle. The prevailing hypothesis focuses on the effects of comorbidity-driven inflammation:

• Systemic Inflammation: Chronic inflammation and oxidative stress lead to coronary microvascular endothelial dysfunction.
  
  
• Myocardial Stiffening: The activated endothelium secretes factors that promote interstitial and perivascular fibrosis (scarring) and increase the stiffness of cardiomyocytes.
  
  
• Diastolic Dysfunction: The stiff, noncompliant ventricle cannot relax effectively, causing a significant rise in left ventricular end-diastolic pressure (LVEDP) and pulmonary congestion, particularly during exertion.
  
  

This model underscores why simply addressing volume overload is often insufficient; the underlying organ-level damage must be targeted.

Recognizing HFpEF Phenotypes (Clustering for Precision)

The heterogeneous nature of HFpEF demands a shift toward phenotype-specific management. Grouping patients by underlying drivers may optimize therapeutic outcomes:

• Hypertensive/Fibrotic Phenotype: Dominated by long-standing hypertension, concentric remodeling, and marked diastolic stiffness.
  
  
• Obese/Metabolic Phenotype: Characterized by high cardiac output, systemic inflammation, and large volume status.
  
  
• Amyloidosis/Infiltrative Phenotype: These specific causes require targeted, non-standard therapies.
  
  

Recognizing the predominant phenotype helps clinicians move beyond a “one-size-fits-all” approach to selecting personalized, guideline-directed medical therapy.

Diagnostic Challenges: Algorithm-Based Confirmation

Diagnosing HFpEF can be challenging, as symptoms often overlap with other non-cardiac conditions. The diagnosis requires objective evidence of underlying structural or functional cardiac abnormalities consistent with diastolic dysfunction and/or elevated filling pressures.

Multi-Modality Imaging and Biomarkers

Echocardiography remains the cornerstone of diagnosis, providing crucial parameters for assessing diastolic function.

• Echocardiographic Markers: Key indicators include the E/e’ ratio (a non-invasive estimate of filling pressure), the Left Atrial Volume Index (LAVI), and the peak tricuspid regurgitation (TR) velocity.
  
  
• Natriuretic Peptides (NP): Measurement of NT-proBNP or BNP is highly valuable. Clinicians must note that obesity can lead to spuriously lower NP values, necessitating a lower diagnostic threshold in these patients.
  
  

The HFA-PEFF and H2FPEF Scores

To standardize the diagnostic process, several scoring algorithms have been validated:

These scores guide the need for confirmatory testing, which may include exercise stress echocardiography or, in equivocal cases, invasive hemodynamic assessment (right heart catheterization).

Modern Pharmacologic Therapy: Guideline-Directed Management

The treatment paradigm for HFpEF has been fundamentally transformed. Current guidelines (AHA/ACC/HFSA 2022 and ESC 2023 Focused Update) now support specific pharmacologic strategies.

The Four Pillars of HFpEF Treatment (ESC 2023 & AHA/ACC/HFSA 2022)

The current guideline-directed medical therapy (GDMT) focuses on drugs demonstrated to reduce heart failure hospitalizations and cardiovascular mortality.

SGLT2 Inhibitors: The Cornerstone Therapy

SGLT2 inhibitors, namely empagliflozin and dapagliflozin, hold the strongest recommendation for broad treatment.

• Evidence: The EMPEROR-Preserved and DELIVER trials demonstrated a significant and consistent reduction in cardiovascular death or heart failure hospitalization across the full spectrum of LVEF ≥ 40%.
  
  
• Clinical Placement: SGLT2 inhibitors are recommended as a Class I indication in patients with HFpEF, regardless of diabetes status.
  
  

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) (Sacubitril/Valsartan)

The role of ARNi remains significant, particularly in the lower end of the preserved ejection fraction spectrum.

• Evidence: The PARAGON-HF trial suggested a substantial benefit in patients with an LVEF below the median (LVEF < 57%) and a greater absolute risk reduction in women.
  
  
• Clinical Placement: ARNi is a Class IIa or IIb recommendation for reducing hospitalizations and mortality in select patients, especially those with LVEF near the 40-50% range.
  
  

Mineralocorticoid Receptor Antagonists (MRA) (Spironolactone/Eplerenone)

MRAs target myocardial fibrosis and systemic inflammation.

• Evidence: The TOPCAT trial showed a reduction in heart failure hospitalizations.
  
  
• Clinical Placement: MRAs are a Class IIa/IIb recommendation for selected patients who have elevated BNP levels and/or are hospitalized for heart failure, provided close monitoring for hyperkalemia and worsening renal function is feasible.
  
  

Diuretics and Comorbidity Management

Effective treatment requires aggressive management of predisposing comorbidities and symptom control.

• Diuretics (Loop/Thiazide): Essential for managing signs and symptoms of volume overload.
  
  
• Comorbidity Control: Aggressive blood pressure control and management of atrial fibrillation are critical components of the therapeutic strategy.
  
  

Special Considerations and Future Directions

Management of Key Comorbidities

• Atrial Fibrillation (AF): AF is highly prevalent in HFpEF and significantly worsens prognosis. Management should focus on aggressive rate control and restoring sinus rhythm where feasible.
  
  
• Iron Deficiency: Correction of iron deficiency should be considered, as it is an independent predictor of poor outcomes.
  
  
• Obesity and Type 2 Diabetes (T2DM): Weight loss (e.g., via GLP-1 agonists) has been shown to improve cardiac structure and function. T2DM management must prioritize agents with proven cardiovascular safety.
  
  

Emerging Therapies and Clinical Trials

Research continues to explore new avenues:

• Anti-Fibrotic Agents: Drugs specifically targeting collagen deposition are under investigation.
  
  
• Targeted Therapies for Amyloidosis: Specific agents (e.g., TTR stabilizers) are standard for patients diagnosed with transthyretin amyloid cardiomyopathy.
  
  

Key Takeaways for Clinical Practice

The management of heart failure with preserved ejection fraction (HFpEF) has finally moved beyond treating symptoms alone. Clinicians must adopt a rigorous, evidence-based approach centered on early diagnosis and the prompt initiation of effective GDMT.

• Diagnosis: Utilize standardized scoring systems (HFA-PEFF, H2FPEF) and objective data (E/e’, NT-proBNP).
  
  
• Cornerstone Therapy: SGLT2 inhibitors are the mandatory, first-line Class I treatment for reducing hospitalizations across the entire HFpEF spectrum, regardless of diabetes status.
  
  
• Layered Therapy: Consider layering therapy with ARNi (especially LVEF < 57%) and MRAs (in selected patients), following guideline-directed, phenotype-driven principles.
  
  
• Comorbidity Management: Aggressive control of hypertension, obesity, AF, and prompt identification/treatment of iron deficiency are essential for improving patient outcomes.